Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged patent prosecution · clear
A few weeks ago, we published the top five fastest growing patent firms . We also talked about the challenges the sector is facing and some of the concerns of law firms with shrinking profits in recent years ( Patexia Insight 54 ) . This week, we are…
No, my site did not get overrun by the pharmaceutical pushers that like to submit "advice" in the comments section. The title is referring to entity size (i.e., undiscounted, small, or micro). This posts will compare the three entity types on…
Below is an animated visualization of the subject matter eligibility 101 roller coaster that patent prosecutors and examiners have been on over the past 5 years. The visualization (interactive version available here , registration required) looks at…
Last Wednesday, we released our Patent Prosecution Intelligence Report for 2019 , where we have ranked the top 1,000 most active and best performing patent firms as well as patent owners (companies, universities, etc.). For this study, we looked at 2.2…
A few weeks ago we published an article ( Patexia Insight 54 ), explaining why patent prosecution is becoming commoditized and why some of the AM LAW 100 are clearly abandoning their patent prosecution practices in favor of more profitable work. This…
A few weeks ago, we discussed how patent prosecution practice is becoming commoditized. Since then, a number of firms and attorneys have contacted us and explained how their work and its quality sets them apart from all others. They claim their clients do…
As we prepare to release our first Patent Prosecution Intelligence Report , we have been hearing from many of practitioners that it is getting much harder to run a profitable practice these days, if they are only doing patent prosecution. This week, we…
On April 25th, a Fed. Cir. panel of Judges Taranto, Clevenger and Chen affirmed the unenforceability of two Merck patents covering a drug presently marketed as Sovaldi(r) to treat hepatitis C, sofosbuvir. Gilead Sciences, Inc. v. Merck & Co., Appeal Nos.…
Prosecutor’s Tool Box 2017 Patent prosecutors navigate complex USPTO rules and seemingly esoteric examinational requirements to procure patent rights. In doing so, it is easy to lose sight of the fact that the Manual of Patent Examining Procedure…
In Regeneron Pharmaceuticals v. Merus N.V. , [16-1346] the Federal Circuit denied rehearing and rehearing en banc the July panel decision, previously discussed here , that litigation misconduct warranted a finding of inequitable conduct in patent…
Broadest Reasonable Does not Mean Broadest Possible! The USPTO applies a broadest reasonable claim interpretation (BRI) to patents and patent applications. The abbreviation “BRI” is often used to reference the full claim interpretation…
What Exactly is the "Thrust of the Rejection?" Every so often a decision comes out of the USPTO's Patent Trial & Appeal Board (PTAB) or the Federal Circuit that has immediate value for patent prosecutors . For example, back in June, the…
